@article{fdi:010086932,
  title = {{F}actors associated with variation in single-dose albendazole pharmacokinetics : a systematic review and modelling analysis},
  author = {{W}hittaker, {C}. and {C}hesnais, {C}{\'e}dric and {P}ion, {S}{\'e}bastien and {K}amgno, {J}. and {W}alker, {M}. and {B}asanez, {M}. {G}. and {B}oussinesq, {M}ichel},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground {A}lbendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. {P}revious work has shown that the drug's pharmacologically active metabolite, albendazole sulfoxide, is characterised by substantial inter-individual pharmacokinetic variation. {T}his variation might have implications for the efficacy of albendazole treatment, but current understanding of the factors associated with this variation remains incomplete. {M}ethodology/{P}rincipal findings {W}e carried out a systematic review to identify references containing temporally disaggregated data on the plasma concentration of albendazole and/or (its pharmacologically-active metabolite) albendazole sulfoxide following a single oral dose. {T}hese data were then integrated into a mathematical modelling framework to infer albendazole sulfoxide pharmacokinetic parameters and relate them to characteristics of the groups being treated. {T}hese characteristics included age, weight, sex, dosage, infection status, and whether patients had received a fatty meal prior to treatment or other drugs alongside albendazole. {O}ur results highlight a number of factors systematically associated with albendazole sulfoxide pharmacokinetic variation including age, existing parasitic infection and receipt of a fatty meal. {A}ge was significantly associated with variation in albendazole sulfoxide systemic availability and peak plasma concentration achieved; as well as the clearance rate (related to the half-life) after adjusting for variation in dosage due to differences in body weight between children and adults. {R}eceipt of a fatty meal prior to treatment was associated with increased albendazole sulfoxide systemic availability (and by extension, peak plasma concentration and total albendazole sulfoxide exposure following the dose). {P}arasitic infection (particularly echinococcosis) was associated with altered pharmacokinetic parameters, with infected populations displaying distinct characteristics to uninfected ones. {C}onclusions/{S}ignificance {T}hese results highlight the extensive inter-individual variation that characterises albendazole sulfoxide pharmacokinetics and provide insight into some of the factors associated with this variation.},
  keywords = {},
  booktitle = {},
  journal = {{PL}o{S} {N}eglected {T}ropical {D}iseases},
  volume = {16},
  numero = {10},
  pages = {e0010497 [16 p.]},
  ISSN = {1935-2735},
  year = {2022},
  DOI = {10.1371/journal.pntd.0010497},
  URL = {https://www.documentation.ird.fr/hor/fdi:010086932},
}